Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The ReVeRA-301 study has ...
Enrollment of the first patient in Europe represents continued progress in the global execution of ReVeRA-301 as we advance our pivotal Phase 3 program,” said David Bharucha, M.D., PhD, FACC, Chief ...
MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of ...
Milestone Pharmaceuticals has enrolled the first Canadian participant in its ongoing multinational Phase III clinical trial, ReVeRA-301, which is evaluating etripamil nasal spray to treat atrial ...
Add Yahoo as a preferred source to see more of our stories on Google. Data collected in this trial are supporting a single-study supplemental NDA registration pathway in AFib-RVR. Credit: Orawan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results